The introduction of array-based comparative genomic hybridization (array CGH) marked a significant advancement in genome-wide analysis of chromosomal imbalances. This technique involves labeling patient and reference DNA with different fluorochromes (or dyes) and applying them in equal parts to a chip. The chip, a glass slide, contains thousands of DNA probes arranged in a high-density grid (array). The patient and reference DNA compete to bind to these probes based on their relative quantities. Using laser scanners and computer processing to detect the color or fluorescence signals, this method identifies genomic regions in the patient DNA that are either deleted (present in reduced amounts) or duplicated (present in increased amounts) compared to the reference DNA. The resolution of array CGH can range from 100 kb to less than 10 kb, depending on the number of DNA probes used, whereas traditional chromosome analysis has a maximum resolution of about 5 Mb.
Besides offering high-resolution genome-wide analysis, array CGH also allows for customized formats with very high-resolution, chromosome-specific arrays, or custom-designed arrays tailored to specific chromosome regions as defined by the researcher. However, a limitation of array CGH, when compared to conventional chromosome analysis, is that it cannot detect balanced chromosomal changes, such as translocations, or low-grade mosaicism.
For more information on the CGH+SNP array technique, please visit our page on molecular karyotyping.
Indications for CMA:
Postnatal
●Patients with developmental delay, neurological abnormalities and signs of dysmorphia with unremarkable chromosome analysis
●Patients with changes that appear balanced under light microscopy
●Patients with a known imbalance that needs to be characterized more precisely
●Patients with a marker chromosome
Prenatal
●Clarification of a non-inherited chromosomal alteration
●Sonographic abnormality with a normal chromosome
Literature
Kleemann et al. 2009, Prenat Diagn 29:1213 / Heinrich et al. 2009, J Lab Med 33(5):255 / Hochstenbach et al. 2009, Eur J Med Genet 52:161 / Menten et al. 2006, J Med Genet 43:625
WAYS TO PARTNER WITH US
TarCET IVD Kits
CE-IVD kits containing reagents
for hereditary indications in
an easy-to-use kit form
Technology Transfer
Out-of-the-box genetics workflow
from sequencing to reporting
for non-invasive prenatal testing
Contact Us
Please get in touch with us
for any questions, inquiries,
feedback, or with any
comments you might have.
BLOG ARTICLES
Carrier screening is a genetic test designed to identify whether an individual carries a gene with changes (mutations) associated with inherited diso…
Trisomy 13, also known as Patau syndrome, is a genetic condition in which cells in the body have three copies of chromosome 13 instead of two. The co…
The human brain develops through a complex series of events, with genes carefully regulating the formation of neurons and glial cells. A recent study…
Rare diseases affect between 300 and 400 million people worldwide – more than cancer and AIDS combined [1, 2], but despite this, many people face a…
Rosalind Elsie Franklin was a brilliant and meticulous research scientist whose interdisciplinary work made fundamental contributions to various area…
February, designated as Cancer Awareness Month, marks a time to reflect on the remarkable progress made in cancer research and to inspire hope for th…
Introduction Cardiovascular disease (CVD) is a major health issue as it remains a leading cause of death worldwide [1]. CVD is responsible for mor…
Antimicrobial resistance (AMR) is one of the most pressing global health threats, and accurate identification and surveillance of multidrug-resistant…
Colorectal cancer remains a significant health concern globally. While genetic factors play a crucial role in its development, identifying the exact …
A new meta-analysis links trans-kingdom gut microbiota (bacteria, eukaryotes, viruses, archaea) to immune checkpoint inhibitor (ICI) response in canc…
